Helena Wright @Moonwater: "𝙄𝙨 𝙩𝙝𝙚 𝙃𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚 "𝙂𝙤𝙡𝙙 𝙍𝙪𝙨𝙝"..."

South Africa

𝙄𝙨 𝙩𝙝𝙚 𝙃𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚 "𝙂𝙤𝙡𝙙 𝙍𝙪𝙨𝙝" 𝙅𝙪𝙨𝙩 𝙀𝙣𝙩𝙚𝙧𝙞𝙣𝙜 𝙋𝙝𝙖𝙨𝙚 𝟮? Many investors feel they missed the boat on the parabolic runs of $LLY (Eli Lilly & Co) and $NVO. But the "First Wave" was about proof of concept. The 𝙎𝙚𝙘𝙤𝙣𝙙 𝙒𝙖𝙫𝙚 is about 𝘼𝙘𝙘𝙚𝙨𝙨𝙞𝙗𝙞𝙡𝙞𝙩𝙮 𝙖𝙣𝙙 𝙎𝙘𝙖𝙡𝙚. 🌊 I recently shared a video analysis on the four pillars that will define the health sector in 2026 on LinkedIn. Here is the investor’s breakdown: 𝙏𝙝𝙚 "𝘾𝙡𝙤𝙣𝙞𝙣𝙜" 𝘾𝙖𝙩𝙖𝙡𝙮𝙨𝙩 (𝘽𝙞𝙤𝙨𝙞𝙢𝙞𝙡𝙖𝙧𝙨) As biosimilars (high-tech generic versions) hit the market, costs drop, but volume explodes. This opens massive emerging markets that were previously priced out. 🌍 Watch: PFE, $TEVA (Teva Pharmaceutical Industries ADR), SNY 𝙏𝙝𝙚 "𝘽𝙞𝙜 𝙁𝙤𝙤𝙙" 𝙋𝙞𝙫𝙤𝙩 The "GLP-1 Effect" is real. Major players in the snack industry are no longer fighting the health trend; they are joining it. Look for companies shrinking portions but hiking protein content to maintain margins. 🥨Watch: $PEP (PepsiCo), NESN.VX (Nestlé), MDLZ 𝙏𝙝𝙚 𝘿𝙚𝙖𝙩𝙝 𝙤𝙛 𝙩𝙝𝙚 𝙉𝙚𝙚𝙙𝙡𝙚 💉 ➡️ 💊 The biggest barrier to mass adoption of weight-loss and metabolic drugs has been the injection. The transition to Oral GLP-1s is the "iPhone moment" for pharma. With NVO’s oral Wegovy launch and LLY’s pill pipeline, the "ease of use" factor could increase the total addressable market five times. 𝘿𝙚𝙛𝙚𝙣𝙨𝙞𝙫𝙚 𝙂𝙧𝙤𝙬𝙩𝙝 Insurance giants are shifting toward proactive health assessments. By using AI to catch risks early, they are protecting their bottom line. Watch: $UNH (UnitedHealth), CVS 𝙒𝙝𝙮 𝘿𝙞𝙫𝙚𝙧𝙨𝙞𝙛𝙞𝙘𝙖𝙩𝙞𝙤𝙣 𝙞𝙨 𝙩𝙝𝙚 𝙍𝙚𝙖𝙡 𝙋𝙡𝙖𝙮 💊📊 The real story isn't just about the "breakthroughs"—it is about Product Line Concentration. The impact of these "Health Revolution" pillars varies wildly based on a company's business mix. Just because a company has a "healthy" product doesn't mean the entire stock is a buy. 𝙏𝙝𝙚 𝘾𝙤𝙣𝙘𝙚𝙣𝙩𝙧𝙖𝙩𝙞𝙤𝙣 𝙍𝙞𝙨𝙠 ($𝙇𝙇𝙔 & $𝙉𝙑𝙊) We’ve seen incredible growth here, but look at the numbers: LLY (Eli Lilly): In late 2025, GLP-1 drugs (Mounjaro/Zepbound) accounted for over 54% of total revenue. When half your revenue comes from one "pillar," the stock is highly sensitive to that specific market. It’s a "Pure Play" success story, but it lacks the safety of a diversified portfolio if pricing pressures hit. 𝙏𝙝𝙚 "𝘿𝙚𝙛𝙚𝙣𝙨𝙞𝙫𝙚 𝙋𝙞𝙫𝙤𝙩" 𝙞𝙣 𝘽𝙞𝙜 𝙁𝙤𝙤𝙙 ($𝙋𝙀𝙋, 𝙈𝘿𝙇𝙕) The shift to protein-packed, smaller snacks is a survival tactic, not a total business makeover. For a giant like PEP (PepsiCo), healthy snacks might only represent a small fraction of their total global product lines. Success in the "healthy snack" pillar doesn't automatically offset potential volume declines in their legacy high-sugar beverage or traditional snack divisions. Performance will likely be fragmented, not uniform. 𝙏𝙝𝙚 𝘽𝙞𝙤𝙨𝙞𝙢𝙞𝙡𝙖𝙧 𝙀𝙣𝙜𝙞𝙣𝙚 (𝙏𝙀𝙑𝘼, 𝙋𝙁𝙀) Biosimilars are the "second wave" growth engine for generic giants. For TEVA, biosimilars are a high-growth segment, but they still operate a massive legacy generic business that faces different margin pressures. You must look at the % of business being migrated to these high-margin biosimilars to see if it actually "moves the needle" for the whole company. 𝙏𝙝𝙚 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙎𝙝𝙞𝙛𝙩 (𝙋𝙞𝙡𝙡𝙨 𝙫𝙨. 𝙄𝙣𝙟𝙚𝙘𝙩𝙞𝙤𝙣𝙨) The move to oral pills is the ultimate "Mass Market" play. I’m looking for companies where the oral pipeline represents a high % of their future growth strategy, rather than just a "nice-to-have" alternative. 𝙏𝙝𝙚 𝘽𝙤𝙩𝙩𝙤𝙢 𝙇𝙞𝙣𝙚 𝙛𝙤𝙧 𝟮𝟬𝟮𝟲 We are moving from a "high-margin/low-volume" model to a "mass-market/high-utility" model in healthcare. Diversification beyond just the "Big Two" is becoming essential for a 2026 portfolio. Don’t just buy the "trend"—buy the Exposure. * A 10% improvement in a "healthy" product line won't save a company if 90% of their business is in declining legacy categories. Look for Companies where the Health Revolution pillars represent a growing and significant percentage of their total revenue. What’s your strategy? Are you betting on the "Pure Plays" or looking for the "Pivoting Giants"? Let’s talk numbers in the comments! 👇

Not investment advice. The author may have financial interests in the mentioned instruments.